---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-120731"
form_type: "8-K/A"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-11-22T23:59:59+00:00"
generated_at: "2026-06-07T22:09:08.318061+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunome files Morphimmune historical financials: 2022 net loss $7.5M, cash $7.2M

## Summary
- Morphimmune 2022 net loss of $7.5M (2021: $2.8M); accumulated deficit $11.2M as of Dec 31, 2022.
- As of Dec 31, 2022, cash $7.2M, total assets $7.3M, total liabilities $0.8M.
- R&D expense $4.2M in 2022 (2021: $0.5M); G&A $3.3M (2021: $1.6M).
- Merger closed Sep 29, 2023; pro forma combined financials filed as Exhibit 99.3.

## SEC filing metadata
- accession: 0001104659-23-120731
- form_type: 8-K/A
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-11-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923120731/0001104659-23-120731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923120731/tm2330767d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-120731
- JSON: https://secwatch.observer/filing/0001104659-23-120731.json
- Plain text: https://secwatch.observer/filing/0001104659-23-120731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.